TGFBR1 and cancer: This suggests the potential use of SB505124 in bone diseases characterized by increased bone formation and mineralization, also including some human cancers, such as prostate cancer, where high expression of TβRI ligands is known to play a key role in tumour progression and indicates a poor prognosis for the patient (Mu et al., 2011 ▸).